Friday, 16 October 2026European Markets

ADC SIIC Stock Is 29% Up In The Last 5 Sessions

Loading stream...

belgium-based real estate investment firm adc siic has gained attention following a significant upswing in their market value. over the last five sessions, the company's share price appreciated by 29.63%, moving from eur0.05 to eur0.07 as of tuesday at 17:37 est. this level of performance sharply diverges from the trend witnessed in france's cac 40 index, which reduced by 0.82% during the same period, closing at eur7,436.61.

performance analysis of adc siic

the closing price for adc siic stood at eur0.07 last friday. this marks an 11.88% drop from its 52-week high value of eur0.08 - a data point suggesting the potential for future growth. however, investors must also be cognizant of various risk indicators, such as the company's negative earnings per share (eps) of eur-0.01.

profitability versus revenue growth

when assessing profitability, adc siic has not been optimal so far. the return on equity ratio, which measures the profitability level by comparing profits generated to shareholders' equity, registers a negative 1.87% over the trailing twelve-month period.

on the other hand, the firm has shown impressive strides when it comes to revenue growth. adc siic managed to increase their quarterly revenue year-on-year by an astounding 351.3%. presently, they maintain a trailing twelve-month revenue of 1.01m. the strong revenue growth indicates a likely successful expansion of their business operations, albeit the existence of potential cost management issues.

in closing

in essence, adc siic might confront short-term difficulties given its current status. nevertheless, their swift increase in revenue dictates a promising long-term investment potential, especially as the firm penetrates the lucrative parisian property markets. therefore, potential long-term gains should carefully be balanced against current profitability metrics when making determinations on investment returns.

more news about adc siic (aldv.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com